BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19010821)

  • 1. Antisense MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive [corrected] and androgen-insensitive [corrected] prostate cancer cells to radiation.
    Udayakumar TS; Hachem P; Ahmed MM; Agrawal S; Pollack A
    Mol Cancer Res; 2008 Nov; 6(11):1742-54. PubMed ID: 19010821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo.
    Mu Z; Hachem P; Hensley H; Stoyanova R; Kwon HW; Hanlon AL; Agrawal S; Pollack A
    Prostate; 2008 May; 68(6):599-609. PubMed ID: 18196567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenovirus E2F1 overexpression sensitizes LNCaP and PC3 prostate tumor cells to radiation in vivo.
    Udayakumar TS; Stoyanova R; Hachem P; Ahmed MM; Pollack A
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):549-58. PubMed ID: 21195876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy.
    Udayakumar T; Shareef MM; Diaz DA; Ahmed MM; Pollack A
    Semin Radiat Oncol; 2010 Oct; 20(4):258-66. PubMed ID: 20832018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination.
    Mu Z; Hachem P; Agrawal S; Pollack A
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):336-43. PubMed ID: 14751501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells.
    Nguyen KH; Hachem P; Khor LY; Salem N; Hunt KK; Calkins PR; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):238-46. PubMed ID: 15993550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.
    Zhang Z; Wang H; Prasad G; Li M; Yu D; Bonner JA; Agrawal S; Zhang R
    Clin Cancer Res; 2004 Feb; 10(4):1263-73. PubMed ID: 14977824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.
    Itsumi M; Shiota M; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    J Mol Endocrinol; 2014 Aug; 53(1):31-41. PubMed ID: 24780839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation.
    Mu Z; Hachem P; Agrawal S; Pollack A
    Prostate; 2004 Aug; 60(3):187-96. PubMed ID: 15176048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
    Ray RM; Bhattacharya S; Johnson LR
    Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.
    Zhang Z; Li M; Wang H; Agrawal S; Zhang R
    Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11636-41. PubMed ID: 13130078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
    Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
    Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.
    Tovar C; Higgins B; Kolinsky K; Xia M; Packman K; Heimbrook DC; Vassilev LT
    Mol Cancer; 2011 May; 10():49. PubMed ID: 21539745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epibrassinolide-induced apoptosis regardless of p53 expression via activating polyamine catabolic machinery, a common target for androgen sensitive and insensitive prostate cancer cells.
    Obakan P; Arisan ED; Coker-Gurkan A; Palavan-Unsal N
    Prostate; 2014 Dec; 74(16):1622-33. PubMed ID: 25214240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation-mediated abrogation of androgen signaling: an in vitro model of prostate cell inflammation.
    Debelec-Butuner B; Alapinar C; Varisli L; Erbaykent-Tepedelen B; Hamid SM; Gonen-Korkmaz C; Korkmaz KS
    Mol Carcinog; 2014 Feb; 53(2):85-97. PubMed ID: 22911881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense Bcl-2 sensitizes prostate cancer cells to radiation.
    Mu Z; Hachem P; Pollack A
    Prostate; 2005 Dec; 65(4):331-40. PubMed ID: 16015611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo.
    Stoyanova R; Hachem P; Hensley H; Khor LY; Mu Z; Hammond ME; Agrawal S; Pollack A
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1151-60. PubMed ID: 17637390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heavy ion radiation-induced DNA damage mediates apoptosis via the Rpl27a-Rpl5-MDM2-p53/E2F1 signaling pathway in mouse spermatogonia.
    Li H; Zhang H; Huang G; Dou Z; Xie Y; Si J; Di C
    Ecotoxicol Environ Saf; 2020 Sep; 201():110831. PubMed ID: 32535367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constant Degradation of the Androgen Receptor by MDM2 Conserves Prostate Cancer Stem Cell Integrity.
    Vummidi Giridhar P; Williams K; VonHandorf AP; Deford PL; Kasper S
    Cancer Res; 2019 Mar; 79(6):1124-1137. PubMed ID: 30626627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.